 Results multicenter trial imipenem/cilastatin intra-abdominal infections multicenter study tobramycin/clindamycin intra-abdominal infections Acute Physiology Chronic Health Evaluation APACHE II index severity patients infection ninety patients evaluable logistic regression outcome abdominal site infection outcome mortality significant correlation APACHE II score residual effect treatment assignment significant improvement outcome imipenem/cilastatin-treated patients differences outcome failure rate patients gram-negative organisms tobramycin/clindamycin-treated patients incidence fasciitis reoperation prosthetic fascial replacement Maximum peak tobramycin levels tobramycin/clindamycin patients gram-negative organisms maximum peak micrograms/mL time peak days maximum peak micrograms/mL days study inclusion severity statistical analyses outcome results notion imipenem/cilastatin therapy intra-abdominal site infection amino-glycoside-based regimen